Published Studies Related to Humalog Mix50/50 (Insulin Lispro Subcutaneous)
Well-designed clinical trials related to Humalog Mix50/50 (Insulin Lispro Subcutaneous)
AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. [2008.04]
Effects of smoking cessation, acute re-exposure and nicotine replacement in smokers on AIR inhaled insulin pharmacokinetics and glucodynamics. [2008.04]
A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. [2008.02]
A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. [2008.02]
A morning dose of insulin glargine prevents nocturnal ketosis after postprandial interruption of continuous subcutaneous insulin infusion with insulin lispro. [2007.12]
Insulin glulisine: a faster onset of action compared with insulin lispro. [2007.09]
AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. [2007.07]
A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone. [2007.07]
Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. [2007.03]
Effect of inhaled insulin on patient-reported outcomes and treatment preference in patients with type 1 diabetes. [2007.02]
Efficacy of short term continuous subcutaneous insulin lispro versus continuous intravenous regular insulin in poorly controlled, hospitalized, type 2 diabetic patients. [2006.09]
Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. [2006.05]
Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients. [2006.04]
Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. [2005.10]
Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. [2005.09]
Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. [2005.08]
A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. [2005.07]
Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system. [2005.05]
Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes. [2005.05]
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. [2005.05]
Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis. [2004.09.01]
Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes. [2004.09]
A randomised controlled trial of insulin lispro given before or after meals in pregnant women with type 1 diabetes--the effect on glycaemic excursion. [2004.06]
Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. [2004.04]
Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. [2004.04]
Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. [2004.01]
Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study. [2004]
Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits. [2003.12]
Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. [2003.11]
Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus. [2003.06]
Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin. [2002.11]
Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. [2002.11]
Post-prandial glucose excursions following four methods of bolus insulin administration in subjects with type 1 diabetes. [2002.04]
Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. [2002.03]
A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. [2001.11]
Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection. [2001.10]
Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes. [2001.07]
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. [2000.12]
Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. [2000.09]
Improved blood glucose variability, HbA1c insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study. [2000.05]
Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. [1999.08]
Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. [1999.05]
Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. [1999.03]
Optimal administration of lispro insulin in hyperglycemic type 1 diabetes. [1999.01]
The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. [1998.12]
Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes. [1998.10]
Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. [1998.06]
Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. [1998.05]
Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. [1998.05]
Effect of physicochemical variables of regular insulin formulations on their absorption from the subcutaneous tissue. [1998.04]
Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin? [1998.03]
Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin. [1998.01]
Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation. [1997.12]
Insulin lispro in CSII: results of a double-blind crossover study. [1997.03]
Well-designed clinical trials possibly related to Humalog Mix50/50 (Insulin Lispro Subcutaneous)
Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. [2006.01]
What is the role of between meal snacks with intensive basal bolus regimens using preprandial lispro? [1999.04]
Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. [1997.02]
Other research related to Humalog Mix50/50 (Insulin Lispro Subcutaneous)
Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. [2008.05.20]
Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion. [2008.02]
Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. [2008]
[Lipoatrophy associated with rapid-acting insulin analogues in young patients with type 1 diabetes mellitus] [2008]
Lispro insulin-induced lipoatrophy: a new case. [2007.12]
Prevailing therapeutic regimes and predictive factors for prandial insulin substitution in 26 687 children and adolescents with Type 1 diabetes in Germany and Austria. [2007.12]
Novel microneedle patches for active insulin delivery are efficient in maintaining glycaemic control: an initial comparison with subcutaneous administration. [2007.07]
Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues. [2007.07]
Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. [2007.06]
The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. [2007.06]
Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections. [2007]
Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. [2007]
Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs. [2007]
Other possibly related research studies
[New developments in the treatment and monitoring of type 1 diabetes mellitus] [2008.05]
|
